Middle East Pharmaceutical Industries Co. (4016.SR)
SAR 129.6
(1.09%)
SAR 129.6
(1.09%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 3.16 Million SAR | -66.67% |
| 2022 | 9.5 Million SAR | -40.0% |
| 2021 | 15.84 Million SAR | -23.08% |
| 2020 | 20.59 Million SAR | 0.0% |
| 2019 | - SAR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 1.58 Million SAR | -50.0% |
| 2024 Q2 | - SAR | -100.0% |
| 2023 Q4 | 3.16 Million SAR | 0.0% |
| 2023 Q1 | - SAR | -100.0% |
| 2023 Q3 | 3.16 Million SAR | -50.0% |
| 2023 Q2 | 6.33 Million SAR | 0.0% |
| 2023 FY | 3.16 Million SAR | -66.67% |
| 2022 Q3 | 9.5 Million SAR | 0.0% |
| 2022 FY | 9.5 Million SAR | -40.0% |
| 2022 Q4 | 9.5 Million SAR | 0.0% |
| 2022 Q1 | - SAR | 0.0% |
| 2021 FY | 15.84 Million SAR | -23.08% |
| 2020 FY | 20.59 Million SAR | 0.0% |
| 2019 FY | - SAR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Al-Dawaa Medical Services Company | 1.44 Billion SAR | 99.781% |
| Nahdi Medical Company | 870.56 Million SAR | 99.636% |
| Al-Razi Medical Co. | 1.77 Million SAR | -78.521% |
| Almujtama Alraida Medical Co. | - SAR | -Infinity% |